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the hospital perspective of costs from hospital admission through 
discharge. A decision analysis model was developed to incorporate 
costs and outcomes associated with prophylaxis treatment success 
or failure, which resulted in the need for empirical therapy and 
developing fungal infection. Clinical outcomes for no prophylaxis 
were derived from a review of published literature. Clinical out- 
comes for prophylaxis with micafungin were based on the results 
of the clinical study. Published literanlre was used to assess hospi- 
tal costs associated with I ISCT patients treated with prophylaxis 
treatment, reated with empirical anti-fimgal treatment, and with 
a probable or proven infection. The cost per course of micafungin 
was varied as part of a sensitivity analysis. In addition, sensitivity 
analyses were performed to evaluate the impact of all assmnptions 
on hospital results. RESULTS. Hospital costs were $136,000 per 
episode for proven/probably infection, $91,000 for empirical ther- 
apy, and $64,000 for no empirical therapy. The model indicated 
that mean total hospital costs were $81,500 for patients with no 
prophylaxis compared to $69,200 for micafimgin prophylaxis. The 
results of the model were sensitive to assumptions about he need 
for empirical therapy and likelihood of developing a fungal infec- 
tion. CONCLUSION. Micafnngin prophylaxis n HSCT reduces 
hospital costs compared to no prophylaxis. Micafungin treatment 
reduces hospital costs due to: (1) decreased use of empirical anti- 
fungal therapy and (2) lower rates of probable and proven fungal 
infection. 
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LIPOSOMAL AMPHOTERICIN B (AMB) PROPHYLAXIS IS SAFE AND 
EFFECTIVE IN PREVENTING INVASIVE FUNGAL.INFECTIONS (IFI) IN 
RELATED AND UNRELATED ALLOGENEIC STEM CELL TRANSPLANTA- 
TION (ASCT) 
OstlJdewo, I4 Coolle3', E.; Bessmertny, 0.; DiNatale, J.; Gm'vin, J.; 
Gzi1"o, M.S. ChildveMr Hospital ofNew FoT"k PresbyteHmT, Cohtmbia 
University, New Yo'rk, NY. 
IFI especially with Aspergilhis (ASG) (10-20%) is a leading 
cause of infectious mortality in ASCT recipients (Wingard, 
BBMT 5:55, 1999). Fhiconazolc (F) prophylaxis has been the 
standard approach to prevent IFI (7% failures) (Goodman et aI, 
NEJM 326:845, 1992; Slavin et al, JID 171:1545, 1995). F is, how- 
ever, ineffective against ASG IFI compared to Amphotericin B
(AmphoB) or AmB. Walsh et al (NJEM 340:764, 1999) reported 
that AraB compared to AmphoB in pts developing fever/neutrope- 
nia (45 % BMT pts) was associated with significantly fewer break- 
through IFI (3.2 vs. 7.8%, p<0.009), less infusion related reac- 
tions, and less nephrotoxicity (both p<0.001). We initiated a pilot 
study to determine the safety and efficacy of prophylactic AraB in 
ASCT recipients. 26 pts (29 ASCT) without previous history of 
IFI were given Arab (3 mg/kg/day) IV (day 0-100). Median age 8 
yrs (0.5-22), 8 F, 18 M. Dx: 5 ALL (3 CR2, 2 CR3), 4 HD (2 
CR2, 1 PR2, 1 PD), 2 AML (1 CR1, 1 Rel), 1 APL CR1, 2 NHL 
CR2, 3 CML, 1 Wihns' PD, 1 NBL PR, 1 Hurler's, 1 WAS, 1 
HLH, 1 SAA, 1 SS, 2 'Fhal. 3 pts had a second ASCT for graft 
failure, tILA typing class A and B (serology) and class II DRBI 
(high resolution) were performed. Donors: 16 UCB: 4 5/6 class l, 
10 4/6 (6 double class I, 4 class I/II mismatch); 9 R-PBSC (8 6/6 
and l 5/6) and 3 6/6 R-BM. 15 ASCT were myeloablative, 14 sub- 
myeloablative. GVHD prophylaxis: tacrolimus/mycophenolate 
mofetil (MMF) n=28; cyclosporine/MMF/prednisone n=l. 
Results: 4/29 ASCT (13%) required premedication for fever and 
rigors. Median follow-up is 2 I2d (28-62 Id). 2 t% developed grade 
3 elevated creatinine while 35% had correctable _>grade 3 
hypokalemia 2 ° to multiple nephorotoxiris. No pt had AraB dis- 
continued for toxicity. Incidence of >grade 2 AGVtID and 
CGVHD was 48% and 7%, respectively. Most importantly, 
despite 48% AGVHD there was only one (3.5%) docmnented IFI 
(Candida parapsilosis) and no (0%) ASG IF1. Estinmted 1-yr OS is 
61.5% and no deaths 2 ° to IFI and no evidence of IFI on 3/3 
autopsies. These prelimina W results suggest prophylactic Arab is 
tolerable and effective in preventing IFI post ASCT, especially 
ASG IFI. Larger randomized studies are needed to determine 
overall safety and long-term efficacy of this approach compared to 
standard prophylaxis regimens to prevent ASG IH. 
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SAFETY OF OUTPATIENT HIGH DOSE ORAL BUSULFAN IN PATIENTS 
UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT) 
Emami, M., Comlnghmz, D.G.; Llo/land, H.K.; Mo'lTis, L.E. The Blood 
mzd Mar'row 7)vnsplant Gl"oap of Georgia at Not'thside Hospital, 
Atla,Tta, GA. 
One hundred and fifty-four consecutive patients received a mye- 
loablative oral busulfan (Bu) containing preparative r gimen prior to 
I ICT. Patients were screened fbr compliance and provided compre- 
hensive verbal and written education prior to chemotherapy initia- 
tion. After screening, seven patients were excluded due to medica- 
tion noncompliance (3), insurance requiring hospitalization (1), and 
hospitalization for a febrile episode (3). Following a test dose, busul- 
fan area under the concentration curve (AUC) was measured and 
dosage adjustments were made to target an AUC of 1200 ng 
mii1/mL. M1 patients received oral anticonvulsant prophylaxis con- 
sisting of phenytoin or gabapentin. Demographics included a medi- 
an age of 45 years (range 20-68 years) with 66 female and 81 male 
patients. Ninety-six patients underwent an autologous HCT versus 
51 allogeneic HCT for the following diagnoses: 58 Non-Hodgkin's 
lymphoma, 12 Hodgkin's disease, 36 multiple myeloma, 23 acute 
lmtkemia, 12 chronic leukemia, and 6 other diagnoses. Preparative 
regimens consisted of 38 BuCy2, 106 BuCy2 and etoposide, and 3 
other Bu containing regimens. Primary endpoints included number 
of repeat doses secondary to emesis, number of patients hospitalized 
secondary to oral Bu intolerance, and incidence of seizures or veno- 
occlusive disease (VOD). Additional Bu dosing occurred in 26 
patients (17.7%) with a median of 1.5 repeated oses per patient. 
Five patients (3.4%) required hospitalization while receiving oral Bu. 
Of the 135 patients evaluated for Bu adverse events; only 2 (1.5%) 
experienced a generalized seiznre, with one patient having a history 
of a seizure disorder. Based on the Baltimore criteria for VOD diag- 
nosis, only 4 patients (3%) were determined to have VOD, with 2 
patients having lymphoma involvement of the liver prior to HCT. 
VOD resolved in 3 patients and was a contributing cause of death in 
1 patient. Following determination f the Bu test dose AUC, 82 
patients required less than and 13 required more than the standard 
high dose Bu, 16 mg/kg based on ideal body weight. In conclusion, 
with appropriate selection and a comprehensive educational process, 
high dose oral Bu can be safely administered on an outpatient basis 
to patients undergoing HCT. Most patients required a ownward 
adjustment oftheir Bu following determination f the AUC. 
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AMBISONE® I MG/KG/DAY AS EMPIRIC ANTIFUNGAL THERAPY IN 
PATIENTS WITH PROLONGED NEUTROPENIA AND FEVER 
DeUoe, M.; He3&lg, K.; Bromz, E.R.; Essell, jr.; Sig'm, mTd, D.; TieJTze~, 
C.; Keller, S. BMT Pvogram, Jewi.rh Hospital, Cinci~n~ati, OH. 
Empiric use of amphotericin the setting of patients with pro- 
longed neutropenia and fever is frequently complicated by renal 
toxicity. The lipid-based forms of amphotericin are associated 
with much less renal toxicity but are significantly more expensive 
than standard amphotericin B. Since June 1999 we have used 
Ambisome@ at a dose of lmg/kg/day as empiric antifungal thera- 
py. We have reviewed this experience in patients who are neu- 
tropenic (ANC < 500/mL), febrile (T> 380 C for >72 hours) and 
on broad-spectrum antibiotics. Forty-three patients met these cri- 
teria. Of these 14 received allogeneic transplant (9 unrelated, 5
related donors) for CML (5), AML (3), ALL (1), MDS (2), MM 
(1); 10 autologous transplant for NHL (6), MM (3), testis (1); 18 
leukemic induction and 1 high dose chemotx without ransplant. 
All had recdved fluconazole prophylaxis. Twenty-seven of forty- 
three (63%) defervesced within 72 hours of starting Ambisome@ 
lmg/kg/day. Only 1/43 (2.3%) developed a positive fungal blood 
cultur, e while receiving this dose of Ambisolne@ and that was 
Candida kruseii related to an infected central venous catheter. 
One patient had Fusarium detected on bronchoscopy and expired 
despite dose escalation to 5 mg/kg/d. The results of this retro- 
spective review compare f:avorably with trials using Ambisome® 3 
mg/kg/d in this setting. At our institution a 14 day course of 
kanbisome® hng/kg/d in a 70 kg patient costs $1976.24 coin- 
pared to $4940.60 for the same patient reated a 3mg/kg/d. YVhilc 
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confirmation i a randomized trial is needed it appears that Ambi- 
some® 1 mg/kg/d is an efficacious and cost-effective approach to 
empiric antifungal therapy in patients with prolonged neutropenia 
and fever. 
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EX VIVO EXPANDED (EVE) PERIPHERAL BLOOD PROGENITOR CELLS 
(PBPC) DEMONSTRATE RESPIRATORY BURST(RB) AND PHAGOCYTIC 
CAPACITY: A FLOW CYTOMETRIC ANALYSIS 
Tombly,, dll.R.; G,o, R.; Pa,iaglm, 3/1.; Ekh,ld, E.A.; Goolsby, C.; 
Papmltsakis, E. Z; JViilleJ; ~'KM.; ~'Ki, te'r, J.N. Diw;'ioJ2 of Hematol- 
ogy/O,cology, Nortbweste,w U, iversity, C,Oicago, IL. 
One approach to the treatment of transplant-associated n u- 
tropenia is transfusion of EVE-PBPC containing functional gran 
ulocytes and their precursors. YVe developed novel multiparame- 
ter flow cytometric assays to evaluate concomitantly the 
phenotype and function of unselected PBPC cnItured in 
cytokine-enriched media containing G-CSF, GM-CSF, Flt3L, 
IL-3, Epo, and 2% autologous plasma (AP). RB activity was stim- 
ulated with either IMLP or Zymosan plus 5% AP. Phagocytosis 
was evaluated using E. coli-FITC (Orpegen Pharma) and 5% AP. 
Day 13 cultures contained cells with both mature and imraature 
phenotypes: 23.7_+3.2% CD15+/IIb+, 29.1_+2.9% CD15+/l lb- 
/dim, 8.8_+l.8% CD15dim/11b+, and 18.0_+5.0% CD15-/11b+ 
with the remainder CD15-/ l lb-.  RB data are expressed as the 
ratio of the mean fluorescence of stinmlated to unstimulated 
ceils. Gating on the subset of mature granulocytes(CD 15+/11 b+), 
EVE ceils exhibited somewhat less RB activity than normal 
peripheral blood lcukocytes (NPBL) [8.2_+2.5 vs. 15.7-+1.9 
(Zymosan, p<0.04); 1.4-+0.2 vs. 2.3_+0.2 (fMLP, p<0.01)]. Unlike 
the mature granulocytes, the CD15+/1 ib-/dim subset, showed no 
difference in its capacity for RB comparing EVE and NPBL. 
Evaluation over the 13 day culture period showed little change in 
RB activity stimulated by fMLP, whetlaer gated or ungated for 
the mature granulocyte subset. However, with Z~nosan stimula- 
tion, the RB activity of the ungated population increased two- 
fold between days 7 and 13 [1.5+_0.4 vs. 3.0+_0.5 (p = 0.08)]most 
likely reflecting the RB activity of the increasing nmnbers of 
mature monocytes which are better stimulated by Z~nosan than 
fMLP. Phagocytic activity was determined by the ratio of FITC- 
positivity of stimulated to unstimulated samples. EVE cultures 
demonstrated the capacity for phagocytosis akhough less so than 
NPBI, [5.0_+5.2 vs. 48.6_+8.3 percent-FITC-positive (p = 0.008)]. 
In these culture conditions, EVE-PBPC acquire the nentrophil 
functions of RB and phagocytosis but do not demonstrate he full 
capacity of NPBL. This may be attributable to auto-stimulation 
of ,nature granulocytes produced in culture, decreasing the 
capacity for further stimulation. Additional studies need to be 
performed to evaluate the & vivo function of the granulocytic 
progeny of EVE-PBPC. 
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USE OF AMPLICOR® CMV MONITOR(ROCHE)FOR CMV SURVEIL- 
LANCE AFTER BLOOD AND MARROW TRANSPLANTATION 
3dram, L.; Wb#e, M.J.; Pi, ei'ro, L.; Petersol~, C.ff.; Ag,ra, E.D.; Fay, 
',7. I,K; BerJy,/a,, R.B.; Meyel; R.; l/a,ce, E.A. B<~/lor-&Tmmolls CaJ> 
cev Cel~te*', Texas 01~cology, P.A., Dallas, 7X. 
The CMV Antigenemia (CMV Ag) has been a standard for 
CMV surveillance testing over the last few years but must be 
processed within a few honrs of collection due to the instability of 
the white cells. Neutropenic patients lack a sufficient number of 
white cells to even perform the CMV Ag test. The Alnplicor 
CMV naonitor (CMV PCR) is performett on plasma and samples 
can easily be collected 24 hours a day, 7 days a week, We looked at 
268 paired smweillance blood specimens using the CMV Ag and 
CMV PCR. The results of the tests are seen in the table below. If 
a true positive is defined as any patient with either assay positive, 
then the sensitivity of the CMV PCR is 72% and the sensitivity of 
the CMV Ag is 67%. Of the I3 patients who were positive by 
Amplicor CMV, but negative by CMV Ag, 5 had less than 400 
copies/ml and 4 patients had greater than 400, but less than 1000 
copies/ml. When the antigenemia slides were reviewed on CMV 
PCR positive/Ag negative samples, 1positive cell was found for 2 
samples and 1 had several distorted cells that were not initially 
reported as positive. In conclusion, of the paired tests conducted 
in our patient population, the two tests appear to provide similar 
results. The CMV PCR offers the advantages of fewer restrictions 
with sample collection to tilne of testing and can be performed in 
neutropenic patients. Tlne Amplicor CMV Monitor is an effective 
methodology for CMV surveillance in blood and marrow trans- 
plant recipients. 
~ CMV Antigenemia IPOS ~NEG 
_ _ 
[ Amplicor CMV Monitor 1~1 I 229 I 
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CHANGING PATTERNS OF FUNGAL INFECTIONS IN A BLOOD AND 
MARROW TRANSPLANT PROGRAM 
White, 3/I. 1; Scott, E.M. l; Mural, L.-', Sha,dou, R. 1; Sm'aciJlo, G. e; 
Agu,:a, E.Dd, Berry,Ta1~, R.B.1; Fay, .7. ~'K1; Pi, eiro, L.1; ~Smce, E.A. 1 
1, Baylor-&mz,~o,s Omce'r CeTm, Jv Texas 011cology, P.A., Dallas, 77~. 
2, Bccvlor UTfiversity Medical Ce~teJ; Dallas, 7782 
Fungal infections are a significant cause of morbidity and mor- 
talky after blood and naarrow transplantation (BMT). The cause 
of these infections is multifactorial and includes the use of 
broad-spectrmn a tibiotics, epidemiologic exposure (nosocomial 
and conamunity) and the overall state of immunosuppression. 
The early recognition of these pathogens in patients at risk for 
these infections is warranted and essential in reducing naorbidity 
and tnortality. We analyzed our program specific epidemiologi- 
cal database (BugSlug) to see the emerging trends in fungal 
infections in our patient population. Data was collected over a 
18 month period. All fungal isolates were r ported and entered 
into the database. During this tinae period, infections caused by 
Candida species uaade up 53% of the fungal isolates seen in our 
patients. Of the Candida species isolated, I8% were Candida 
glabrata. Of 178 total, 38 blood isolates (21%) occurred in 28 
patients. Of thc 38 blood isolates, 16 (42%) were Candida 
species and 7(18%) were Aspergillus species. There were 19 
(50%) isolates that were considered to be contaminants, both 
clinically and by speciation. All 7 Aspergillus blood isolates were 
felt to be contaminants. Although there were 3 Fusarinm isolates 
in our database, none involved the blood. Although found in 
many specimens in the database, no blood isolates were attribut- 
able to C. albicans. The Candida blood isolates by species are 
summarized in the table below. There have been 17 deaths 
(45%) in the patients who developed fungal blood isolates. Cla- 
dosporium and Curvularia were single isolates in 2 patients; both 
of which were proximate to death. Of 12 patients with can- 
didemia, only 1 remains alive and well, Candida was felt to be 
causative or contributory to death in 7 patients (64%). As with 
many other centers, we are seeing a predominance of can- 
didemia caused by non-albicans species. These organisms remain 
a significant cause of morbidity and mortality in our patient 
population. 
Species I No. of isolates 
~C. glab,-aCa 1 8 
C. k,'use;- ~ 3 - -  
C. lusitaniae i 1 
C. tropicaIis ~ - -  -1 - -  
C. parapsilosis 1 
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